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There is probably no need to explain that mitochondria 
are essential for the functioning of the eukaryotic cell: 
they provide energy through oxidative phosphorylation. 
Mitochondria are the site of synthesis of many 
molecules and are also involved in apoptosis. All 
mammalian eukaryotic cells - in particular somatic 
cells with some exceptions such as red blood cells - 
contain mitochondria: there are several hundred to 
several thousand. Human mitochondria contain their 
own circular genome, 16568 base pairs long, encoding 
13 proteins of the respiratory chain, 2 rRNAs and 22 
tRNAs. The 13 proteins are components of four 
respiratory complexes participating in oxidative 
phosphorylation, but many other proteins of the 
respiratory chain are encoded in the nucleus and 
complex II is only made up of nuclear-encoded proteins 
(Anderson et al., 1981; Andrews et al., 1999). 
The belief that mitochondria are involved in cancer is 
quite old - Warburg (1956) proposed in the early 20th 
century that cancer was due to the lack of oxidative 
respiration. Cancer cells performed glycolysis even 
when oxygen was present. The general idea has been 
discussed in many papers. This phenomenon, as often
in cancer, is not as simple as it was believed to be 
(Mullen et al., 2011; Ward and Thompson, 2012). The
glycolytic phenotype, combined with glutaminolysis, is 
a way to provide the rapidly dividing cells with 
building blocks from molecules which are not degraded 
to carbon dioxide and water in this way. 
Interest in mitochondrial DNA (mtDNA) mutations 
was aroused much later, there were early papers 
pointing out that mitochondria were altered in 
oncocytomas. But the turning point was a paper by 
Vogelstein's group (Polyak et al., 1998) reporting that 
mutations in sequences of tumor mtDNA were found  
(but not in appropriate control tissues). These mutations  
were homoplasmic, which means that all mtDNA 
molecules carried the mutation. At this point many 
groups started to look for these mutations in many 
different types of cancer. Currently, a Medline query of 
"mitochondrial DNA mutations cancer", June 2012, 
gives 1279 hits. 
To try to summarize this amount of data is difficult. 
Mitochondrial DNA has been hailed as an excellent 
marker for detecting tumors, as a possible site of attack 
for anti-cancer drugs. A whole issue of Oncology and 
several books have been devoted to mitochondria and 
cancer. 
To discuss these papers in more detail, some more 
information on mitochondrial DNA is required. At 
present, this molecule has been sequenced in many 
thousands of individuals. But even earlier partial 
sequences and restriction analysis led to the grouping 
of various subgroups of mtDNA sequences into groups 
of related sequences with a common ancestor called: 
haplogroups. Mitochondrial DNA originated in Africa 
from where it spread to other continents. In Europe, for 
instance, haplogroups H, U, I, J, K, V, X, T and W are
the most common. Each haplogroup is composed of 
subhaplogroups, very numerous for instance in the cas  
of haplogroup H. As mitochondrial DNA is maternally 
inherited, which does not recombine (but it is still not a 
closed matter), there is a set of characteristic 
mitochondrial DNA positions for each haplogroup. As 
mitochondrial DNA is easy to analyze, many papers 
have appeared linking various haplogroups to both 
positive (longevity) and negative (increased frequency 
of Alzheimer's disease etc.) effects (Wallace, 2005). 
In general, mtDNA sequences are compared to a 
reference sequence, called the Cambridge Reference  
Sequence (CRS), originally determined by Sanger and 
co-workers (Anderson et al., 1981) and corrected later  
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(revised Cambridge sequence, rCRS, Andrews et al., 
1999). It is important to understand that this 
comparison is for the sake of standardization, but it 
really does not mean anything, except that the analyzed 
DNA is not the same as that of the standard. 
Essentially, in recent papers, a full classification up to 
subhaplogroups is made on the basis of the sequence of 
the entire mitochondrial genome; but for "older" papers 
(a field started in the late 1990s), often only parts of the 
sequence were analyzed. 
There are many papers stating that various mutations 
have been found in tumors which were not found in an 
appropriate control tissue. Here we come to one of the 
numerous problems with many of the published papers 
- the ones we will discuss is appropriate reference 
material, appropriate control tissue, appropriate number 
of analyzed samples and appropriate standards of 
analysis. 
The reference material has been mentioned above - it is
the rCRS. However, comparison of patients' mtDNA 
sequences to the rCRS is not sufficient to warrant 
conclusions that these differences have anything to do 
with cancer - they are simply different from the 
reference sequence, as are most analyzed mitochondrial 
DNAs. This has not been understood by some of the 
authors. 
The second problem is standards. Salas, Bandelt and 
co-workers (Salas et al., 2005; Bandelt and Salas, 
2009) have pointed out that in many of the papers 
combinations of haplogroup-specific sites are found in 
some mtDNA sequences which can only be explained 
as a mix-up or contamination of the analyzed samples. 
Such mtDNA molecules would not exist in a cell. 
These authors even go as far as to discredit essentially 
all or most of the papers in the field. This is perhaps 
extreme, as especially in more recent papers careful 
analysis with assignment to subhaplogroups is made, 
but it does suggest that the papers should be read with 
caution. 
The appropriate healthy control tissue is also a 
problem. In some papers tumor margins are taken, but 
the theory of field cancerization (Dakubo et al., 2007) 
indicates that tissues at the boundary of a tumor are not 
necessarily normal, and this may also be true for the 
mitochondrial DNA that they contain. Blood is a 
commonly used control and is generally acceptable. 
There is some concern that it may contain tumor-
derived cells or DNA, but these levels of contamination 
are not expected to be high. 
The next problem is a statistical one - how many 
samples have to be analyzed to give a reliable result? 
This is of less importance for mutations, and of more 
importance for papers analyzing whether the fact tha
an individual has a given haplogroup affects his risk of 
getting a defined type of cancer. This has been 
investigated for many cancers and many haplogroups,  
but generally on groups of patients and controls which 
Samuels et al. (2006) consider much too small to draw  
 
reliable conclusions from. 
Many reviews have been published concerning mtDNA 
and cancer, but in very few of them did the authors 
check the original data, thus what is discussed in ma y 
of them may be the result of analyzing a mixture of true 
and false results. 
In a review analyzing numerous mutations Brandon et 
al. (2006) put forth the hypothesis that most mutations 
found in mtDNA in cancer occur at the sites which are
polymorphic in the human population - that is the sit s 
which changed in human evolution. This has been also 
stated by other authors. Briefly, most of these 
mutations would not have strong effects on 
mitochondrial function, though mutations with strong 
effects have been shown to occur in early stages of 
thyroid cancer. It is very difficult to comment on this as 
reanalyzing all the published data would be a daunting 
task, this may not, however, be true for all types of 
cancers. Elegant analysis performed by Skonieczna et 
al. (2012) for colon cancer and a paper on oncocytomas 
(Pereira et al., 2012) have shown that in these two types 
of tumors, which were analyzed by the new high-
throughput sequencing techniques, the mutations which 
are found in the tumors but not in control tissue ar
severe mutations, which would certainly impair 
oxidative phosphorylation. More data are required to 
determine whether these two types of tumors are 
special or whether simply better data is available for 
them. Many of the mutations found by high-throughput 
sequencing techniques are heteroplasmic (He et al., 
2010), that is the mtDNA is a mixture of mutated and 
unmutated molecules. In many cases heteroplasmy 
below a certain level would not have been detected by 
Sanger sequencing, and this is the way most of the data 
in the literature were obtained. 
Another point worth mentioning is whether these 
mutations have any selective value for the tumor. 
Though instinctively the idea of the selection of a 
mutation which somehow drives a cancer cell is 
appealing, there are mathematical models indicating 
that homoplasmy can be established starting by chance 
with a single mutation, without any need for selective 
advantage (Chinnery et al., 2002).  
Of course a mathematical model cannot be proof of 
anything taking place in a living cell, but it  
certainly is an indication of the possibility that at least 
some mutations in mtDNA in cancer cells are there fo  
no special reason. 
One of the more important facts concerning 
mitochondria and cancer is the fact that mutations in 
nuclear genes which are components of complex II of
the respiratory chain cause various types of tumors. 
These mutations have been found in all four subunits of 
succinate dehydrogenase as well as in fumarate 
hydratase. They cause paragangliomas, leiomyomas 
and myomas, and the mechanism is believed to be  
through altering the stability of HIF1 alpha through 
indirect action by fumarate (Baysal et al., 2000; Baysal,  
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2006; Bardella et al., 2011; Burnichon et al., 2010). As 
these complex II mutations affect the mitochondrial 
respiratory chain this is proof that mutations acting on 
mitochondria can cause cancer. However, this does nt 
resolve the problem of the role of mutations in 
mitochondrial DNA. 
Is there any evidence that mtDNA mutations affect 
carcinogenesis or other processes taking place in 
tumors? There are some data which are intriguing. 
Petros et al. (2005) have shown in a mouse model that 
when cells of the prostate cancer cell line PC3 are 
introduced into nude mice, the presence of a well 
known 8993 NARP mutations (in ATP6, which causes 
the disease neurogenic ataxia with retinitis pigmentosa) 
in the mtDNA causes tumors which grow 7 times faster 
that tumors differing only by the absence of this 
mutation from mitochondrial DNA. Moreover, the 
same mutation was shown to stimulate cell growth in a
bone stromal environment (Arnold et al., 2009). In a 
similar set of experiments Shidara et al. (2005) have 
shown that the same mutation present in HeLa cell 
mitochondria causes resistance to apoptosis in tumors 
growing in nude mice in comparison to the results 
obtained with HeLa cells containing wild type 
mitochondrial DNA. This is interesting, but as the 8993 
mutation has never been found in tumors this does nt 
show how a mutation which is present in a natural 
tumor would act. 
While it is difficult to prove the involvement of 
mtDNA mutations in triggering oncogenesis, there is 
increasing evidence of their significance for tumor 
growth and metastatic potential and its regulation 
(Shidara et al., 2005). The first suggestions that 
mtDNA mutations may play a role in metastasis came 
from the comparison of frequency of somatic mtDNA 
mutations in lung carcinoma at different stages of 
tumor formation. It positively correlated with cancer 
progression as well as with metastatic potential 
(Matsuyama et al., 2003). However, such analysis 
could not be considered as a proof, and needed to be 
confirmed experimentally. 
Ishikawa and Hayashi (2009, 2010) addressed this 
problem with a set of experiments based on cybrids. As 
there is no way to transform mammalian mitochondria, 
cybrids or transmitochondrial hybrids are a very usef l 
tool for exploring the role of mtDNA mutations. It is
possible to obtain cells devoid of mitochondrial DNA 
called rho0 cells, generally by prolonged growth in the 
presence of ethidium bromide. Such cells can be 
repopulated by mitochondria derived from other cells, 
which were enucleated to eliminate the influence of the 
nuclear component. Cybrids have the nucleus from 
rho0 cells and the mitochondria of choice. To find the
role of mtDNA mutations, exchange experiments were 
performed between cell lines with high and low 
metastatic capability. Both cell lines were depleted of  
mtDNA to create rho0 cells. Then the rho0 cells from a 
low metastatic cell lines derived from a lung carcinoma 
were fused with high metastatic cytoplasts (cells with 
removed nuclei) and the other way round: rho0s from 
high metastatic cell line were fused with low metastatic 
cytoplasts. The metastatic potential was evaluated in 
mice and it correlated with the presence of "metasta ic" 
mtDNA and not with the "metastatic" nucleus. 
Together with the metastatic potential, complex I 
deficiency observed in the original high metastatic cell 
line (but not in a low metastatic one) was transferred. 
The finding was confirmed for another pair of high/low 
metastatic cell lines with/without complex I deficiency 
respectively derived from fibrosarcoma with similar 
effect. For both "metastatic" mitochondria, mutations in 
mtDNA complex I genes were found (Ishikawa et al., 
2008a). Similar experiments were performed for other 
cancer cells like breast cancer (Imanishi et al., 2011). 
These experiments confirmed in a very elegant way the 
involvement of mtDNA mutations in metastasis, but the
mechanism still may be questioned. As mitochondria as 
a whole and complex I in particular are important 
reactive oxygen species (ROS) generators in the cell 
this was one of the first concepts to explain 
mitochondrial participation in metastasis. ROS are 
natural candidates as they are known to be an important 
cell signaling factors involved, among others, in cell 
cycle control and apoptosis - both disturbed in 
carcinogenesis. 
Higher levels of ROS are frequently observed in cancer 
cells but the source and the way of action seem to be 
pleiotropic and involve several mechanisms like 
hypoxia, paradoxically causing increased ROS 
production, hypoglycemia, oncogenes and transcription 
factors (like RAS, MYC, p53) and others together with 
mtDNA mutations. The multiple possibilities have been 
reviewed in detail by Ralph et al. (2010) and Fogg et al. 
(2011). To present some examples of mitochondrial 
ROS involvement: a coincidence of elevated ROS 
production, mitochondrial defect and enhanced 
tumorigenesis was shown in a mouse model of 
intestinal carcinoma (APCMin/+ mice) crossed to 
produce APCMin/+ Tfam+/- mice.  
TFAM (mitochondrial transcription factor A) is 
responsible for mtDNA transcription and maintenance. 
Homozygous knockout of the gene is lethal, but 
heterozygotes are viable, with no phenotype besides up 
to 50% mtDNA depletion. Interestingly, APCMin/+ 
Tfam+/- mice showed increased tumor number and 
growth as well as ROS production. The role of ROS in 
APCMin/+ model was proven by targeting catalase to 
mitochondria which resulted in reduction of 
tumorigenesis (Woo et al., 2012). Similarly SOD 
inactivation led to increased transformation of 
irradiated mouse embryonic fibroblasts. Increased ROS 
was observed as well by the Hayashi group in cybrid 
experiments but some aspects of ROS measurement 
methods have been questioned (Zielonka and 
Kalyanaraman, 2008). 
At the end it is worth pointing that some activity of 
respiratory chain is required for metastatic potential.  
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Rho0 cells do not generate elevated ROS and do not 
grow in an anchor-independent way as cancer cells 
(Weinberg et al., 2010). Similarly, heteroplasmic 
mutations (frameshifts and nonsense) in ND5 
mitochondrial gene (complex I) show higher ROS 
production and tumor growth than the same mutations 
in a homoplasmic state (Park et al., 2009). Again, no 
enhanced ROS and high metastatic potential was 
observed for the cells with large mtDNA deletion in 
cybrid system (Ishikawa et al., 2008b). This effect may 
be easily explained: as the respiratory chain is a ROS 
producer, when it is completely inactive ROS are not 
elevated and do not influence tumor formation and 
metastasis. 
Another interesting matter is not mutations but 
haplogroups and polymorphisms. For a long time the 
different mitochondrial haplogroups were believed to 
have no effect on the phenotype of the individual in 
whose organism they occurred. Some papers have 
suggested that some haplogroups are responsible for 
more uncoupled mitochondria, which could have 
consequences for their "owners" in respect to their 
utilization of food, and could affect aging and 
susceptibility to various mitochondrial diseases, 
especially Leber's hereditary optic neuropathy, a 
disease for which mitochondrial DNA mutations in 
complex I are necessary but not sufficient and one f 
the predisposing factors is the haplogroup in which the 
mutation is present (Wallace, 2005; Singh and 
Kulawiec, 2009; Kulawiec et al., 2010). There are some 
papers indicating functional differences between 
haplogroups, though the differences have not really 
been proven. However, the literature on haplogroup 
associations with various diseases is also abundant 
(Medline gives 77 hits for mitochondrial haplogroup 
association disease). This has all the problems of 
association studies and few of them have been 
performed on groups which are sufficiently large to 
warrant definitive conclusions. Samuels et al. (2006) 
have stated that in order to ascertain an associatin with 
a common haplogroup with a 95% certainty 2000 
patients and controls would have to be analyzed, very
few studies had even a quarter of the required number 
of cases. 
Breast cancer is a good example how confusing the 
data can be. The site 10398 is polymorphic - in some 
haplogroups an A is present in this position, in others a 
G. There are serious and well-documented papers 
showing an association of the A with breast cancer in 
African women (Canter et al., 2005; Darvishi et al., 
2007), though this has not been confirmed by other 
studies (Setiawan et al., 2008). On the other hand, we 
have shown the association of a G in this position with
breast cancer in Polish women (Czarnecka et al., 2010). 
What does this mean? Perhaps only that the association 
is not as simple as it appears - the effects of the 
nucleotide in this position either are spurious or due to 
complex interactions with nucleotides at other positi ns  
in the mitochondrial genome and also with the nuclear 
genes.However, some of the results are interesting, 
Booker et al. (2006) have shown associations of 
haplogroup U with renal and prostate cancer (relative 
risk of about 2), we have shown various haplogroup 
associations for vulvar cancer, endometrial cancer and 
breast cancer (reviewed in Czarnecka and Bartnik, 
2011). In our analysis we did not find many mutations, 
but what seemed to be true was that many of the 
samples from the patients contained very rare 
polymorphisms of mtDNA - not found or only very 
rarely found in the existing mitochondrial DNA 
databases. Herrnstadt and Howell (2004) have 
suggested that rare polymorphisms are something 
which is common in many diseases, and would be a 
sign of poorer fitness, somehow conducive to a number 
of disease processes. 
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